Compounds > lhrh,(n)-ac-(4-cl-phe)(1)-(4-cl-phe)(2)-trp(3)-phe(6)-alanh2(10)-
Page last updated: 2024-11-12

lhrh,(n)-ac-(4-cl-phe)(1)-(4-cl-phe)(2)-trp(3)-phe(6)-alanh2(10)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LHRH,(N)-Ac-(4-Cl-Phe)(1)-(4-Cl-Phe)(2)-Trp(3)-Phe(6)-AlaNH2(10)-: gonadorelin antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16131121
MeSH IDM0103296

Synonyms (12)

Synonym
org 30093
des-gly(sup 10)-gnrh d-alanylamide
lhrh,(n)-ac-(4-cl-phe)(1)-(4-cl-phe)(2)-trp(3)-phe(6)-alanh2(10)-
d-alaninamide, n-acetyl-4-chloro-d-phenylalanyl-4-chloro-d-phenylalanyl-d-tryptophyl-l-seryl-l-tyrosyl-d-phenylalanyl-l-leucyl-l-arginyl-l-prolyl-
lhrh, (n)-acetyl-4-chlorophenylalanyl(1)-4-chlorophenylalanyl(2)-tryptophyl(3)-phenylalanyl(6)-alaninamide(10)-
unii-yj793bo829
org-30093
(n)-ac-1-(4-cl-phe)-2-(4-cl-phe)-3-trp-6-phe-10-alanh2-lhrh
78493-58-0
gnhr, (n)-ac-(4-cl-phe)(1)-(4-cl-phe)(2)-trp(3)-phe(6)-alanh2(10)-
yj793bo829 ,
DTXSID00229118

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In vitro, the antagonist had no detectable agonist activity in the concentration used, had no effect on the maximal LH release which can be induced by LRH and shifted the dose-response line of LRH to the right, without changing its slope."( Effect of pretreatment of long-term ovariectomized rats with an LRH antagonist on LH release in vitro by LRH, elevated K+ or N6-monobutyryl adenosine 3',5'-monophosphate (mbcAMP) plus theophylline.
van Dieten, JA; van Rees, GP, 1985)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (90.91)18.7374
1990's1 (9.09)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.71 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
theophylline
[no description available]		1.9610dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
buserelin
Buserelin: A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications.		2.3820oligopeptide
monobutyryl cyclic amp
monobutyryl cyclic AMP: RN given refers to parent cpd. N(6)-butyryl-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the exocyclic amino group on the purine fragment is carrying a butyryl substituent.		1.96103',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
butanamides		protein kinase agonist
bucladesine
Bucladesine: A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed). bucladesine : A 3',5'-cyclic purine nucleotide that is the 2'-butanoate ester and 6-N-butanoyl derivative of 3',5'-cyclic AMP.		1.96103',5'-cyclic purine nucleotide
trelstar
Triptorelin Pamoate: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Neoplasms
[description not available]		01.9610
Cancer of Pituitary
[description not available]		01.9610
Pituitary Neoplasms
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.		01.9610
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9610
Cancer of Prostate
[description not available]		01.9610
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		01.9610